Sugi Predict

Sugi Predict / Compounds / SCHEMBL198207

SCHEMBL198207

SCHEMBL198207

O=C(Nc1cc(OCC2CCCN2)cc(C(F)(F)F)c1)c1cccnc1Nc1ccc2cn[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 4/20 0.55
▸ TUBB4A P04350 1/20 0.45
▸ TUBB P07437 1/20 0.45
▸ TUBA3C P0DPH7 1/20 0.45
▸ TUBA1B P68363 1/20 0.45
▸ TUBA4A P68366 1/20 0.45
▸ TUBB4B P68371 1/20 0.45
▸ TUBB3 Q13509 1/20 0.45
▸ TUBB2A Q13885 1/20 0.45
▸ TUBB8 Q3ZCM7 1/20 0.45
▸ TUBA3E Q6PEY2 1/20 0.45
▸ TUBA1A Q71U36 1/20 0.45
▸ TUBA1C Q9BQE3 1/20 0.45
▸ TUBB6 Q9BUF5 1/20 0.45
▸ TUBB2B Q9BVA1 1/20 0.45
▸ TUBB1 Q9H4B7 1/20 0.45
▸ HPGD P15428 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903045 1.00 KDR (0.55) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3902473 0.89 KDR (0.56) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6054239 0.87 KDR (0.54) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4569926 0.87 KDR (0.54) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6054243 0.87 KDR (0.54) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL13867920 0.87 KDR (0.54) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3890580 0.87 KDR (0.54) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3894314 0.86 KDR (0.54) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL187826 0.86 KDR (0.56) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL13867940 0.86 KDR (0.56) KDRTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100074909-A1 Combinations for the treatment of cancer AMGEN INC (US) 2010-03-25 — — US claimed
JP-4338974-B2 — — 2009-10-07 — — JP claimed
US-7514564-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2009-04-07 — — US claimed
EP-1915151-A2 COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS Amgen, Inc (US) 2008-04-30 — — EP claimed
WO-2006102504-A2 COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS AMGEN INC (US) 2006-09-28 — — WO claimed
US-20060216288-A1 Combinations for the treatment of cancer AMGEN INC (US) 2006-09-28 — — US claimed
US-7105682-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2006-09-12 — — US claimed
EP-1467721-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS Amgen Inc. (US) 2004-10-20 — — EP claimed
JP-2004527499-A — — 2004-09-09 — — JP claimed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 — — US claimed
WO-2002068406-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS AMGEN INC. (US) 2002-09-06 — — WO claimed
EP-3170824-B1 A 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVE AS C-MET INHIBITOR AMGEN INC (US) 2020-07-01 — — EP disclosed
US-20190185572-A1 COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF HOFFMANN-LA ROCHE INC. (US) 2019-06-20 — — US disclosed
EP-3330292-A1 HUMAN C-FMS ANTIGEN BINDING PROTEINS Amgen, Inc (US) 2018-06-06 — — EP disclosed
US-9988457-B2 Human C-FMS antigen binding proteins AMGEN INC. (US) 2018-06-05 — — US disclosed
US-20060040966-A1 e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases AMGEN INC. 2006-02-23 — — US disclosed
WO-2006012374-A1 SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-02-02 — — WO disclosed
US-20060018909-A1 Angiopoietin-2 specific binding agents AMGEN INC. 2006-01-26 — — US disclosed
US-20050118643-A1 Specific binding agents to hepatocyte growth factor AMGEN INC 2005-06-02 — — US disclosed
WO-2005017107-A2 SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR AMGEN INC. (US) 2005-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060216288-A1 Combinations for the treatment of cancer TP53, VHL, FOLR2 KDR 2043/4885TUBB4A 66/4885TUBB 44/4885
US-20030195230-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KDR 13/4885TUBB4A 969/4885TUBB 927/4885
US-20060040966-A1 e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases EDNRA, PTGIS, EDNRB KDR 4/4885TUBB4A 3225/4885TUBB 3866/4885
US-20100074909-A1 Combinations for the treatment of cancer TP53, VHL, FOLR2 KDR 2043/4885TUBB4A 66/4885TUBB 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.